Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228


Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial.

Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR.

Haematologica. 2019 Apr 4. pii: haematol.2018.214429. doi: 10.3324/haematol.2018.214429. [Epub ahead of print]


Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH.

Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.


Curative potential of hematopoietic stem cell transplantation for advanced psoriasis.

Ciurea SO, Hansrivijit P, Ciurea AM, Hymes S, Chen J, Rondon G, Hosing C, Popat U, Champlin RE.

Am J Hematol. 2019 Jun;94(6):E176-E180. doi: 10.1002/ajh.25470. Epub 2019 Apr 3. No abstract available.


Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.

Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2019 Feb 11. pii: S1083-8791(19)30097-7. doi: 10.1016/j.bbmt.2019.02.002. [Epub ahead of print]


Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.

Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH.

Biol Blood Marrow Transplant. 2019 May;25(5):1039-1044. doi: 10.1016/j.bbmt.2019.01.009. Epub 2019 Jan 11.


Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.

Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK.

Am J Hematol. 2019 Mar;94(3):E72-E74. doi: 10.1002/ajh.25375. Epub 2018 Dec 21. No abstract available.


Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement.

Jensen GL, Dabaja BS, Pinnix CC, Gunther JR, Huen A, Duvic M, Oki Y, Fanale M, Hosing C, Milgrom SA.

Case Rep Oncol. 2018 Nov 12;11(3):721-728. doi: 10.1159/000494081. eCollection 2018 Sep-Dec.


Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation.

Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K.

Front Immunol. 2018 Oct 23;9:2444. doi: 10.3389/fimmu.2018.02444. eCollection 2018.


Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS.

Lancet Haematol. 2018 Nov;5(11):e532-e542. doi: 10.1016/S2352-3026(18)30156-X.


Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy.

Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC.

Adv Radiat Oncol. 2018 Jul 12;3(4):639-646. doi: 10.1016/j.adro.2018.07.001. eCollection 2018 Oct-Dec.


Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy.

Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e51-e61. doi: 10.1016/j.clml.2018.09.002. Epub 2018 Sep 10.


Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.

Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO.

Bone Marrow Transplant. 2019 Apr;54(4):601-606. doi: 10.1038/s41409-018-0367-2. Epub 2018 Oct 18.


Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia.

Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D.

Biol Blood Marrow Transplant. 2019 Mar;25(3):505-514. doi: 10.1016/j.bbmt.2018.09.032. Epub 2018 Oct 9.


Melphalan-based autologous transplant in octogenarian multiple myeloma patients.

Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH.

Am J Hematol. 2019 Jan;94(1):E2-E5. doi: 10.1002/ajh.25310. Epub 2018 Oct 31. No abstract available.


Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.

Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO.

Bone Marrow Transplant. 2018 Sep 26. doi: 10.1038/s41409-018-0344-9. [Epub ahead of print]


Is a matched unrelated donor search needed for all allogeneic transplant candidates?

Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE.

Blood Adv. 2018 Sep 11;2(17):2254-2261. doi: 10.1182/bloodadvances.2018021899.


High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.

Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH.

Leuk Lymphoma. 2019 Feb;60(2):442-452. doi: 10.1080/10428194.2018.1485908. Epub 2018 Jul 22.


Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers.

Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML.

Clin Cancer Res. 2018 Aug 15;24(16):3845-3856. doi: 10.1158/1078-0432.CCR-17-2707. Epub 2018 Jul 17.


Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.

Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2197-2203. doi: 10.1016/j.bbmt.2018.07.010. Epub 2018 Aug 9.


Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.

Rudoni J, Jan A, Hosing C, Aung F, Yeh J.

Eur J Haematol. 2018 Sep;101(3):389-398. doi: 10.1111/ejh.13127. Epub 2018 Jul 27.


Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.

Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE.

Blood. 2018 Jun 28;131(26):2989-2992. doi: 10.1182/blood-2018-02-832360. Epub 2018 May 16. No abstract available.


A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA.

Haematologica. 2018 Sep;103(9):e416-e418. doi: 10.3324/haematol.2018.187617. Epub 2018 Apr 5. No abstract available.


Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.

Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1602-1609. doi: 10.1016/j.bbmt.2018.02.020. Epub 2018 Mar 2.


Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma.

Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1146-1154. doi: 10.1016/j.ijrobp.2018.01.003. Epub 2018 Jan 6.


Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion.

Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K.

Blood. 2018 Mar 15;131(11):1248-1257. doi: 10.1182/blood-2017-07-798751. Epub 2018 Jan 31.


Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.


Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.

Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e41-e50. doi: 10.1016/j.clml.2017.10.001. Epub 2017 Oct 12.


Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.

Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM.

Bone Marrow Transplant. 2018 Mar;53(3):315-325. doi: 10.1038/s41409-017-0034-z. Epub 2017 Dec 21.


Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β2-adrenergic receptor.

Agha NH, Baker FL, Kunz HE, Graff R, Azadan R, Dolan C, Laughlin MS, Hosing C, Markofski MM, Bond RA, Bollard CM, Simpson RJ.

Brain Behav Immun. 2018 Feb;68:66-75. doi: 10.1016/j.bbi.2017.10.001. Epub 2017 Oct 7.


Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1232-1236. doi: 10.1016/j.bbmt.2017.09.005. Epub 2017 Sep 14.


Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.

Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M.

Eur J Haematol. 2017 Dec;99(6):532-535. doi: 10.1111/ejh.12970. Epub 2017 Oct 8.


Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.

Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2166-2171. doi: 10.1016/j.bbmt.2017.08.021. Epub 2017 Aug 24.


Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease.

Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM.

Am J Surg Pathol. 2017 Nov;41(11):1483-1490. doi: 10.1097/PAS.0000000000000914.


A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.

Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2018 Feb;59(2):515-518. doi: 10.1080/10428194.2017.1344906. Epub 2017 Jul 3. No abstract available.


False-positive HIV nucleic acid amplification testing during CAR T-cell therapy.

Ariza-Heredia EJ, Granwehr BP, Viola GM, Bhatti M, Kelley JM, Kochenderfer J, Hosing C.

Diagn Microbiol Infect Dis. 2017 Aug;88(4):305-307. doi: 10.1016/j.diagmicrobio.2017.05.016. Epub 2017 Jun 3.


Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q.

Cancer. 2017 Sep 15;123(18):3568-3575. doi: 10.1002/cncr.30770. Epub 2017 May 17.


Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.

Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1359-1366. doi: 10.1016/j.bbmt.2017.05.002. Epub 2017 May 12.


A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.

Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C.

Br J Haematol. 2017 Aug;178(4):561-570. doi: 10.1111/bjh.14731. Epub 2017 May 9.


Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO.

Leukemia. 2017 Jul;31(7):1654-1657. doi: 10.1038/leu.2017.118. Epub 2017 Apr 12. No abstract available.


Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma.

Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1059-1063. doi: 10.1016/j.bbmt.2017.03.030. Epub 2017 Apr 4.


The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.

Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S.

Leuk Res. 2017 Jul;58:14-22. doi: 10.1016/j.leukres.2017.03.008. Epub 2017 Mar 22. Review.


Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).

Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM.

Ann Oncol. 2017 Jul 1;28(7):1554-1559. doi: 10.1093/annonc/mdx163.


Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO.

Blood. 2017 Jun 1;129(22):3031-3033. doi: 10.1182/blood-2017-02-766154. Epub 2017 Mar 28. No abstract available.


Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ.

Br J Haematol. 2017 May;177(3):457-466. doi: 10.1111/bjh.14570. Epub 2017 Mar 14.


Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.

Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM.

Br J Haematol. 2017 May;177(4):567-577. doi: 10.1111/bjh.14596. Epub 2017 Mar 14.


Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma.

Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C.

Transfusion. 2017 Apr;57(4):1052-1057. doi: 10.1111/trf.14016. Epub 2017 Feb 10.


Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes.

El Chaer F, Shah DP, Kmeid J, Ariza-Heredia EJ, Hosing CM, Mulanovich VE, Chemaly RF.

Cancer. 2017 Jun 15;123(12):2329-2337. doi: 10.1002/cncr.30599. Epub 2017 Feb 8.


Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY.

Mol Ther. 2017 Jan 4;25(1):285-295. doi: 10.1016/j.ymthe.2016.10.020. Epub 2017 Jan 4.


Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2017 Apr;23(4):581-587. doi: 10.1016/j.bbmt.2017.01.005. Epub 2017 Jan 4.


The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y.

Br J Haematol. 2017 Mar;176(5):750-758. doi: 10.1111/bjh.14477. Epub 2016 Dec 16.

Supplemental Content

Loading ...
Support Center